Protein Biomarkers in Serum of Patients with Schizophrenia

This study was devised to identify potential biomarkers of schizophrenia (SP) using proteomics techniques. We obtained 44 serum specimens from patients with SP, 26 specimens from patients with depression, and 40 specimens from healthy controls. Immobilized metal affinity capture protein chips (IMAC30) and surface-enhanced laser desorption-ionization time-of-flight mass spectrometry were used to isolate and obtain mass spectrometric data of differentially expressed serum proteins. The sequences of the peaks discrepant among the study groups were obtained using matrix-assisted laser desorption/ionization mass spectrometry and proteins identified using Mascot database. In the SP group, there were 91 protein peaks that were different from other study groups at the p value of < 0.05 and 54 peaks different at the p value of < 0.01. Two protein peaks at the mass-to-charge ratio of 1,207.41 and 1,466.78 were markedly different among the study groups, with the lowest expression in specimens from patients with SP. The amino acid sequences were, respectively, Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg (EGDFLAEGGGVR) and Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg (DSGEGDFLAEGGGVR). These proteins were identified as the N-terminal fragments of fibrinogen. In conclusion, these biomarker proteins may be useful for molecular diagnosis of SP.